Tuesday, April 14, 2026
← Back to archivePolicy
Policy•Fierce Pharma•Apr 14, 2026
Despite uncertainties, Travere’s Filspari emerges as first FDA-approved FSGS treatment
background ▾
- •Filspari is the first FDA-approved treatment for FSGS, addressing a previously untreated rare kidney disease with significant unmet medical need.
- •The approval came despite a prior negative phase 3 result and extended regulatory review, suggesting strong clinical or regulatory rationale that overcame initial concerns.
- •Reimbursement strategy, real-world patient access, and competitive positioning in rare kidney disease treatment will be critical to monitor going forward.
Travere TherapeuticsFilspari
→ Read original articlePolicy•Pharmaceutical Technology•Apr 14, 2026
MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority
background ▾
- •FDA priority review grants ifinatamab deruxtecan expedited pathway (RTOR + Project Orbis) for ES-SCLC, indicating substantial clinical advantage potential over existing options in a high-unmet-need indication
- •Asset builds on breakthrough therapy designation (August 2025) and Phase II data showing promising efficacy signals in a disease with minimal post-progression alternatives
- •Monitor October 2026 FDA decision date and international approvals under Project Orbis; commercial success will depend on comparative efficacy, safety profile, and pricing/reimbursement landscape in ES-SCLC
Merck & CoDaiichi Sankyoifinatamab deruxtecanpembrolizumab
→ Read original articlePolicy•Fierce Biotech•Apr 13, 2026
FDA urges clinical trial sponsors to report the results of their studies
background ▾
- •30% of clinical trials lack publicly reported results, creating a significant publication bias that obscures drug development failures and safety signals from clinicians and researchers.
- •FDA is escalating enforcement with a coordinated reminder to 2,200+ sponsors and explicit authority to impose fines up to $10,000 for non-compliance with the one-year reporting deadline.
- •Watch for which sponsors receive formal non-compliance letters and whether the FDA sustains enforcement momentum beyond the initial reminder phase, as historical enforcement has been sparse (8 non-compliance letters since 2021).
AcceleronOcugen
→ Read original articlePolicy•Fierce Pharma•Apr 14, 2026
Pfizer rebuked by FDA for misleading Adcetris ads on Facebook
background ▾
- •FDA issued a warning letter to Pfizer for inadequate risk communication in Adcetris Facebook advertisements, specifically citing missing indication, contraindications, and safety information
- •This reflects heightened regulatory enforcement of digital pharma marketing compliance and the tension between social media platform limitations and FDA advertising standards
- •Monitor whether Pfizer's corrective actions and industry responses signal tighter FDA scrutiny of social media promotional tactics across the sector
PfizerAdcetrisbrentuximab vedotin
→ Read original articlePolicy•Fierce Pharma•Apr 14, 2026
UPDATED: Replimune to reduce workforce following 'disappointing' second rejection for melanoma prospect
background ▾
- •RP1 has now been rejected twice by the FDA, indicating persistent regulatory concerns that resubmission did not fully address
- •Replimune is implementing cost-cutting measures including workforce reduction in response to the clinical and commercial setback
- •The repeated rejection signals potential challenges in the oncolytic immunotherapy space and raises uncertainty about RP1's viability or the need for additional pivotal trial data
ReplimuneRP1
→ Read original articleMarket Access
Market Access•Fierce Biotech•Apr 13, 2026
Kailera outlines plans for $528.5M IPO to support quartet of Chinese obesity assets
background ▾
- •Kailera's injectable ribupatide achieved ~18% mean weight loss in Chinese phase 3 trial, potentially positioning it as best-in-class, though no head-to-head data versus Zepbound exists
- •IPO proceeds will fund three concurrent global phase 3 trials for injectable ribupatide through Q2 2028, with oral ribupatide phase 3 initiation planned for Q2 2028
- •Watch for: phase 3 trial data readouts (KAI-7535 expected later this year), Western market trial initiation, and regulatory filing timelines in US/EU
KaileraJiangsu Hengrui PharmaceuticalsEli Lillyribupatide (injectable)ribupatide (oral)KAI-7535
→ Read original articleMarket Access•STAT News•Apr 14, 2026
Opinion: My brother can’t access a just-approved breakthrough drug for his rare disease
background ▾
- •Avlayah approved but labeled only for pediatric patients ≤16 years, despite scientific evidence supporting efficacy in adults and ongoing Phase 2/3 trials enrolling patients up to age 26
- •Label restriction creates a real-world access gap for adult patients with progressive neurological disease who have no other CNS-penetrating treatment options beyond the existing 20-year-old standard of care (Elaprase)
- •Watch for: potential label expansion application or pediatric strategy shift; off-label prescribing patterns and payer coverage decisions for adult patients; clinical data readout from Phase 2/3 trial that may support label amendment
Denali TherapeuticsFDAAvlayah (tividenofusp alfa-eknm)Elaprase (idursulfase)
→ Read original articleMarket Access•Fierce Biotech•Apr 13, 2026
AbbVie inks $745M deal with Chinese biotech Haisco for two acute pain assets
background ▾
- •AbbVie enters the NaV1.8 inhibitor competitive space following Vertex's Journavx approval and Eli Lilly's SiteOne acquisition, signaling strong pharma confidence in this non-opioid pain mechanism despite Vertex's Phase II setback with a next-generation candidate
- •The $745 million total deal value (with up to $705M in milestones) reflects meaningful upside potential, but both assets remain early-stage (Phase 1 IV formulation and preclinical oral candidate), presenting substantial development and clinical risk
- •Monitor HSK55718 Phase 1 progression and whether AbbVie advances either candidate into pivotal trials; competitive positioning will depend on differentiation versus Journavx and timeline to market
AbbVieHaisco Pharmaceutical GroupVertex PharmaceuticalsHSK55718HSK51155Journavx
→ Read original articleMarket Access•Fierce Pharma•Apr 14, 2026
ViiV launches ‘Still Here’ campaign aimed at reminding young people about HIV
background ▾
- •ViiV is conducting a patient awareness campaign focused on young people with HIV, suggesting a commercial strategy to engage and retain this demographic segment
ViiV HealthcareGSKShionogi
→ Read original articleMarket Access•Fierce Pharma•Apr 14, 2026
Regeneron rides into radiopharma via $2.1B biobucks pact with Australia’s Telix
background ▾
- •Regeneron commits $2.1B to radiopharmaceutical partnership with Telix, signaling major strategic pivot into oncology-focused radiotherapy space
- •Deal structured with milestone payments ('biobucks'), suggesting clinical development dependencies and phased value realization
- •Move diversifies Regeneron's portfolio away from near-term obesity market saturation concerns
RegeneronTelix
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Apr 13, 2026
Spyre points to phase 2 win for ulcerative colitis drug as proof it could take on Takeda’s Entyvio
background ▾
- •SPY001 achieved 40% clinical remission at Week 12, exceeding the 20-25% class benchmark and supporting claims of potential best-in-class efficacy in UC
- •The extended half-life (3x longer than vedolizumab) enables quarterly/biannual dosing, a significant convenience advantage that could drive market differentiation and payer appeal
- •Phase 2b combination data and Phase 3 outcomes remain critical; Spyre's ability to demonstrate sustained efficacy advantage and safety in larger trials will determine competitive threat to Entyvio's ~$2B UC market
Spyre TherapeuticsTakedaSPY001SPY002SPY003
→ Read original articleClinical Trials•Fierce Biotech•Apr 13, 2026
Revolution’s much-hyped RAS inhibitor hits key survival goals in phase 3 pancreatic cancer trial
background ▾
- •Daraxonrasib achieved near-doubling of median OS (13.2 vs. 6.7 months) in second-line metastatic PDAC, hitting both primary OS and PFS endpoints in RAS G12-mutant patients with a manageable safety profile
- •Evaluate projects $4 billion in 2032 sales for daraxonrasib as the most valuable orphan drug in development; Revolution has already secured $2 billion in contingent royalty funding from Royalty Pharma
- •Watch for: FDA approval timeline and regulatory pathway using priority voucher; ASCO 2026 PFS data disclosure; interim readouts from first-line phase 3 trial (monotherapy and combination); competitive positioning versus atebimetinib and other RAS inhibitors; expansion into KRAS G12C NSCLC
Revolution MedicinesRoyalty PharmaImmuneeringdaraxonrasibatebimetinibzoldonrasib
→ Read original articleClinical Trials•Fierce Pharma•Apr 14, 2026
Lilly’s Jaypirca shows fixed-duration power in ‘ambitious’ phase 3 CLL trial win
background ▾
- •Jaypirca is the first BTK inhibitor to demonstrate efficacy with fixed-duration dosing in CLL phase 3, a potentially paradigm-shifting approach versus standard continuous therapy
- •This is Lilly's fourth positive phase 3 readout with Jaypirca in CLL, indicating robust clinical program depth and regulatory pathway clarity
- •Watch for FDA label update timing and whether payers will grant preferential coverage for fixed-duration regimens based on convenience and potential compliance improvements
Eli LillyJaypirca (pirtobrutinib)
→ Read original articleClinical Trials•Endpoints News•Apr 13, 2026
Allogene’s first cut of data on ‘off-the-shelf’ CAR-T shows promise
background ▾
- •Off-the-shelf CAR-T achieved complete remission in >50% of lymphoma patients, validating the allogeneic approach as clinically viable
- •Success in allogeneic CAR-T could disrupt the current autologous landscape by reducing manufacturing complexity and patient access barriers
- •Key unknowns include long-term remission durability, graft-versus-host disease rates, and how this compares to approved autologous CAR-T therapies
Allogene Therapeutics
→ Read original articleClinical Trials•Endpoints News•Apr 13, 2026
BioNTech's HER2 ADC succeeds in Phase 2 study, FDA filing planned
background ▾
- •BioNTech's HER2 ADC met Phase 2 endpoints and will proceed to FDA filing, representing a competitive threat to Roche's Enhertu franchise in oncology
- •The ADC is being positioned for specific patient populations where it may differentiate from the established standard of care
- •Watch for FDA interaction/pre-submission meeting outcomes and the full Phase 2 data readout at major oncology conferences
BioNTechRocheBioNTech HER2 ADCEnhertu
→ Read original article